Highlights
- Market Cap
- $252.69M
- Enterprise Value
- $255.84M
- EPS (TTM)
- -$0.00
- Total Revenue (TTM)
- $1.05M
- Gross Profit (TTM)
- $830.72K
- EBITDA (TTM)
- -$1.21M
- Year Range
- $0.01 - $0.22
- ROA (TTM)
- -11.18%
- ROE (TTM)
- -12.42%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Pharmhouse Corp, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Pharmhouse Corp
- 1D
- 60.29%
- 1M
- 164.60%
- YTD
- 39.15%
- 6M
- 33.63%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 15, 2025, PHSE's average daily return is +2.17%, while the average monthly return is +34.45%. At this rate, your investment would double in approximately 0.2 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jul 2025 with a return of +221.4%, while the worst month was Aug 2025 at -36.3%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.
On a daily basis, PHSE closed higher 44% of trading days. The best single day was May 23, 2025 with a return of +147.9%, while the worst single day was May 22, 2025 at -58.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.05% | -25.88% | 164.60% | 39.15% | |||||||||
| 2025 | -8.39% | 58.55% | 221.35% | -36.27% | 32.71% | -12.38% | 28.32% | -14.58% | 279.11% |
Benchmark Metrics
Pharmhouse Corp has an annualized alpha of 17622.24%, beta of 1.87, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 16, 2025.
- This stock captured 2301.61% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1531.85%) — a profile typical of hedging or uncorrelated assets.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 17,622.24%
- Beta
- 1.87
- R²
- 0.01
- Upside Capture
- 2,301.61%
- Downside Capture
- -1,531.85%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Pharmhouse Corp (PHSE) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pharmhouse Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pharmhouse Corp was 71.05%, occurring on Mar 2, 2026. Recovery took 13 trading sessions.
The current Pharmhouse Corp drawdown is 24.23%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -71.05% | Jul 30, 2025 | 148 | Mar 2, 2026 | 13 | Mar 19, 2026 | 161 |
| -61.71% | May 16, 2025 | 5 | May 22, 2025 | 21 | Jun 24, 2025 | 26 |
| -55.45% | Mar 20, 2026 | 5 | Mar 26, 2026 | — | — | — |
| -21.09% | Jul 9, 2025 | 1 | Jul 9, 2025 | 2 | Jul 11, 2025 | 3 |
| -10.34% | Jul 25, 2025 | 1 | Jul 25, 2025 | 2 | Jul 29, 2025 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pharmhouse Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pharmhouse Corp is priced in the market compared to other companies in the Entertainment industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PHSE relative to other companies in the Entertainment industry. Currently, PHSE has a P/S ratio of 187.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PHSE in comparison with other companies in the Entertainment industry. Currently, PHSE has a P/B value of 13.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |